micro-community-banner
 
  • Saved

3yr
Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis - Discover Oncology

Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis - Discover Oncology

Source : https://link.springer.com/article/10.1007/s12672-022-00538-6

Objectives Response to immune checkpoint inhibitor (ICI) remains limited to a subset of patients and predictive biomarkers of response remains an unmet need, limiting our ability to provide precision medicine....


Conclusions: Mechanisms underlying the clinical predictors of response observed in this real-world analysis, such as genetic variants and bone metastasis-tumor microenvironment, warrant further exploration in larger studies incorporating translational endpoints. Consistently positive clinical correlates may help inform patient stratification...

  • Saved

3yr
T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review - PubMed

T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35960133/

Rationale: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for the treatment of EGFR mutation positive advanced nonsmall cell lung cancer (NSCLC); however, acquired resistance is...


Lesson: The literature review and our report suggest that osimertinib is a promising treatment for NSCLC regardless of histology if T790M is present as an acquired mutation.

  • Saved

3yr
Heterogeneous expression of ACE2, TMPRSS2, and FURIN at single-cell resolution in advanced non-small cell lung cancer - Journal of Cancer Research and Clinical Oncology

Heterogeneous expression of ACE2, TMPRSS2, and FURIN at single-cell resolution in advanced non-small cell lung cancer - Journal of Cancer Research and Clinical Oncology

Source : https://link.springer.com/article/10.1007/s00432-022-04253-1

Purpose Considering the high susceptibility of patients with advanced non-small cell lung cancer (NSCLC) to COVID-19, we explored the susceptible cell types and potential routes of SARS-CoV-2 infection in lung...


Conclusion: Our research first revealed the heterogeneous expression of ACE2, TMPRSS2, and FURIN in different cell subsets of NSCLC and also across different individuals. These results provide insight into the specific cells targeted by SARS-CoV-2 (i.e., cancer cells and alveolar cells) in patients with advanced NSCLC, and indicate that smoking...

  • Saved

3yr
Pneumothorax in lung cancer following anlotinib treatment: A case report

Pneumothorax in lung cancer following anlotinib treatment: A case report

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302245/

Anlotinib is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor, and has been approved for the treatment of patients with advanced nonsmall cell lung cancer who had...


Lessons: Pneumothorax may occur when VEGF is inhibited, which can promote the proliferation and repair of alveolar wall substances, leading to alveolar rupture. With respect to pneumothorax, it is necessary to be aware of the risk of pulmonary bullous rupture during antitumor treatment with small-molecule tyrosine kinase drugs.

  • 3yr
    Never seen it; obviously everything is possible; it though does appear it is more of the issue for those with severe CPOD at baseline
  • Saved

3yr

Highlights from a Gather Session: EGFR-positive Metastatic Non-Small Cell Lung Cancer



NSCLC Connect recently hosted a Q&A session with Oncologists regarding EGFR-positive Metastatic Non-Small Cell Lung Cancer



Below are some highlights from the discussion:



Respondents noted that combined ramucirumab plus erlotinib was generally well-tolerated by patients; however, certain toxicities of concern were noted (e.g., cutaneous reactions, fatigue, hypertension)



For discussions with patients regarding choice of treatment, most respondents offered support, with conversation often focusing on quality of life, survival, and so forth.




  • “I basically tell them that they have an incurable disease, but they have a high likelihood of disease control with disease improvement. And then we talk about if their disease progresses through these agents, that they may be eligible for second- or third-line treatments.”



Patient questions often center around adverse effects, cost, and quality of life.



Some respondents noted that follow-up with imaging, assessment of symptoms, and so forth is key to prognosis when using targeted therapy.




  • “… I will do scan at 8 weeks if they have a lot of issues, or 12 weeks if they're tolerating well, to evaluate how they responded to treatment, and that will help me to make better judgment regarding their prognosis.”

  • “These are patients that have metastatic, incurable disease, so we certainly discuss things with them and their family about the targeted agents and their side effects, as well as their efficacy, and that we'll be doing imaging every 3 or 4 months to assess the effectiveness.”



A few respondents stated they are in want of more robust, longer-term data regarding the efficacy and safety of combined agents vs. a single agent.